Inotropes in the beta-blocker era

Clinical Cardiology

Volumn 23, Issue 3 SUPPL., 2000, Pages

  Lowes, B D ^a   Simon, M A ^a   Tsvetkova, T O ^a   Bristow, M R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Beta blockers; Enoximone; Heart failure; Milrinone; Phosphodiesterase inhibitors

Indexed keywords

BISOPROLOL; CARVEDILOL; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENOXIMONE; METOPROLOL; MILRINONE; MOXONIDINE; PHOSPHODIESTERASE INHIBITOR; TRANSDUCIN;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; HEART AFTERLOAD; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HEART RATE; HUMAN; RECEPTOR OCCUPANCY; SIGNAL TRANSDUCTION; SUDDEN DEATH;

EID: 0033995320     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960231504     Document Type: Article

References (48)

1. Bristow MR: β-adrenergic Receptor Blockade in Chronic Heart Failure. Circulation 2000;101:558-569
2. Bristow MR: Mechanism of action of β-blocking agents. Am J Cardiol 1997;80:26L-40L
3. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the U.S. Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334: 1349-1355
4. CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13
5. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353: 2001-2007
6. Haber HL, Simek CL, Gimple LW, Bergin JD, Subbiah K, Jayaweera AR, Powers ER, Feldman MD: Why do patients with congestive heart failure tolerate the initiation of β-blocker therapy? Circulation 1993;88:1610-1619
7. Carson PG and principal investigator: SR Moxonidine for congestive heart failure - MOXCON (protocol B3N-MC-EUBC). File 266 of the Federal Research in Progress Database. 8-18-98. Maintained by National Technical Information Services, US Dept of Commerce, Springfield, VA. Distributed by Knight-Rider Information via Dialog®
8. Cohn JN: SR Results of the MOXCON Trial, Presented in Late Breaking Clinical Trials, Heart Failure Society of America, 1999
9. Waagstein F, Mobini R, Andersson B, Bergh C-H, Fu ML-X, McNay J: Moxonidine attenuates transmyocardial norepinephrine concentration gradient and total body norepinephrine spillover in congestive heart failure (abstr). Circulation 1998;98:I-780
10. Swedberg K, Bristow MR, Cohn JN, Dargie H, Wright TJ: Marked reduction of plasma norepinephrine by moxonidine SR in chronic heart failure. J Am Coll Cardiol (in press)
11. Lechat P, Escolano S, Golmard JL, Lardoux H, Witchitz S, Henneman JA, Maisch B, Hetzel M, Jaillon P, Boissel JP, Mallet A: Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1997;96:2197-2205
12. Xiao Rui-Ping, Ji X, Lakatta EG: Functional coupling of the β2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol 1995;47:322-329
13. Yatani A, Brown AM: Rapid β-adrenergic modulation of cardiac calcium channel currents by a fast G protein pathway. Science 1989;245:71-74
14. Communal C, Singh K, Colucci WS: Gi protein protects adult rat ventricular myocytes from β-adrenergic receptor-mediated apoptosis. Circulation 1998;98:I-742
15. 1-receptor down-regulation in heart failure. Circ Res 1986;59:297-309
16. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV, Fowler M, Ginsburg R: Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest 1992;89:803-815
17. Bristow MR, Anderson FL, Port JD, Skerl L, Hershberger RE, Larrabee P, O'Connell JB, Renlund DG, Volkman K, Murray J, Feldman AM: Differences in β-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:1024-1039
18. 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 1989;35:295-303
19. Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, Van Dop C: Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 1988;82:189-197
20. i-proteins in heart failure. Lancet 1988;2:936-937
21. Böhm M, Eschenhagen T, Gierschik P, Larisch K, Lensche H, Mende U, Schmitz W, Schnabel P, Scholz H, Steinfath M, Erdmann E: Radioimmunochemical quantification of GIα in right and left ventricles from patients with ischemic and dilated cardiomyopathy and predominant left ventricular failure. J Mol Cell Cardiol 1994;26:133-149
22. 1-adrenergic receptors in the failing human heart. Circulation 1993;87:454-463
23. Feldman MD, Copelas L, Gwathmey JK, Phillips P, Warren SE, Schoen FJ, Grossman W, Morgan JP: Deficient production of cyclic AMP: Pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987;75:331-339
24. Bristow MR, Ginsburg R, Minobe W, Cubiccotti MS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB: Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-211
25. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR: Assessment of the β-adrenergic pathway in the intact failing heart: Progressive receptor down-regulation and subsensitivity to agonist response. Circulation 1986;74:1290-1302
26. Leroy M-J, Degerman E, Taira M, Murata T, Wang LH, Movsesian MA, Meacci E, Manganiello VC: Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf 9 insect cells. Biochemistry 1996;35:10194-10202
27. Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC: Sarcoplasmic reticulum-associated cyclic adenosine 5′-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest 1991;88:15-19
28. Jiang H, Colbran JL, Francis SH, Corbin JD: Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries. J Biol Chem 1992;267:1015-1019
29. Yang J, Drazba JA, Ferguson DG, Bond M: A-kinase anchoring protein 100 (AKAP100) is localized in multiple subcellular compartments in the adult rat heart. J Cell Biol 1998;142:511-522
30. Leier CV: General overview and update of positive inotropic therapy. Am J Med 1986;81(4C):40-45
31. Janicki JS, Shroff SG, Weber KT: Physiologic response to the inotropic and vasodilator properties of enoximone. Am J Cardiol 1987;60(5):15C-20C
32. Tsvetkova TO, Farber DJ, Abraham WT, Kelley P, Eichhorn E, Gilbert EM, Robertson AD, Lindenfeld J, Wolfel EE, Zisman L, Bristow MR, Lowes BD: Comparative hemodynamic effects of milrinone and dobutamine in heart failure patients treated chronically with carvedilol (abstr 135). J Card Fail 1998;4(3, suppl 1):36
33. Böhm M, Deutsch HJ, Hartmann D, LaRosée K, Stäblein A: Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol 1997;30: 992-996
34. Sigmund M, Jakob H, Becker H, Hanrath P, Schumacher C, Eschenhagen T, Schmitz W, Scholz H, Steinfath M: Effects of metoprolol on myocardial β-adrenoceptors and Giα-proteins in patients with congestive heart failure. Eur J Clin Pharmacol 1996; 51:127-132
35. Eichhorn E, Bristow MR: Medical therapy can improve the biological properties of the chronically failing heart. Circulation 1996; 94:2285-2296
36. Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS: Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. J Clin Invest 1984;75:643-649
37. Gilbert EM, Bristow MR, Mason JW: The acute hemodynamic response to low dose enoximone (MDL 17,043): An oral dose-range study. Am J Cardiol 1987;82:57C-62C
38. Dibianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R, for the Milrinone Study Group: A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-683
39. Lowes B, Higginbotham M, Petrovich L, DeWood MA, Weber K, Greenberg M, Rahko PS, Dec GW, LeJemtel T, Roden R, Schleman MM, Robertson AD, Gorczynski RJ, Bristow MR: Low dose enoximone improves exercise capacity in chronic heart failure. J Am Coll Cardiol (in press)
40. Uretsky BF, Jessup M, Konstam M, Dec GW, Leier CV, Benotti J, Murali S, Herrmann HC, Sandberg JA, for the Enoximone Multicenter Trial Group: Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: Lack of benefit compared to placebo. Circulation 1990;82:774-780
41. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, Dibianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayem U, Kukin ML: Effect of oral milrinone on mortality in severe heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325: 1468-1475
42. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F, DeMets DL, White BG, for the Vesnarinone Trial Investigators: A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998;339:1810-1816
43. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, Ferguson DA, Bristow MR: Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998;31:1336-1340
44. Lowes BD, Abraham WT, Dutcher DL, Roden RL, Crisman TS, Minobe W, Port JD, Larrabee P, Gilbert EM, Bristow MR: Comparative anti-adrenergic effects of carvedilol and metoprolol in a randomized, placebo-controlled-trial (abstr). Circulation 1996;94 (suppl 8)I-664
45. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB: Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardromyopathy. Circulation 1989;79:483-490
46. Goldstein S: Increased survival and reduction in hospitalizations with metoprolol CR/XL in the MERIT-HF study (abstr). Circulation 1999;100:I-201-I-202
47. BEST Steering Committee: Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol 1995;75:1220-1223
48. Eichhorn E, Domanski M: Results of the BEST Trial. Late breaking clinical trials. AHA 1999